atenolol has been researched along with Ventricular Dysfunction, Left in 16 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study effects of atenolol and trimetazidine on heart rhythm variability in postmyocardial infarction patients with moderate left ventricular dysfunction." | 9.10 | [Effect of atenolol and trimetazidine on dispersion of cardiac rhythm in patients with moderately expressed postinfarction left ventricular dysfunction]. ( Kaliuzhin, VV; Kamaev, DIu; Solovtsov, MA; Tepliakov, AT, 2002) |
| "To assess antiischemic efficacy, safety and effect on myocardial perfusion of a course treatment with mildronate (as monotherapy and in combination with atenolol) in patients with postinfarction left ventricular dysfunction associated with moderate heart failure." | 9.10 | [The use of fatty acid beta-oxidation inhibitor mildronate as monotherapy or in combination with atenolol in patients with left ventricular dysfunction after myocardial infarction]. ( Mamchur, SE; Sankevitch, TV; Stepatcheva, TA; Teplyakov, AT, 2003) |
| "The aim of this study was to compare the effects on left ventricular function and exercise tolerance of a selective beta-antagonist (atenolol) with those of another selective beta 1-antagonist with vasodilator properties (nebivolol) in patients with ischemic left ventricular dysfunction but no overt congestive heart failure." | 9.08 | Medium-term effects of beta-blockade on left ventricular mechanics: a double-blind, placebo-controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction. ( Chapelle, F; Hager, D; Pouleur, H; Rousseau, MF; Stoleru, L; Van Eyll, C; Van Nueten, L, 1996) |
| "We sought to determine the effect of nifedipine gastrointestinal therapeutic system (GITS) or atenolol on ischemic left ventricular dysfunction induced by mental stress." | 9.08 | Effects of therapy with nifedipine GITS or atenolol on mental stress-induced ischemic left ventricular dysfunction. ( Andrews, TC; Carlson, W; Cummings, N; Friedman, R; Jacobs, S; MacCallum, G; Mannting, F; Muller, JE; Parker, JD; Stone, PH; Tofler, GH, 1998) |
| "To study effects of atenolol and trimetazidine on heart rhythm variability in postmyocardial infarction patients with moderate left ventricular dysfunction." | 5.10 | [Effect of atenolol and trimetazidine on dispersion of cardiac rhythm in patients with moderately expressed postinfarction left ventricular dysfunction]. ( Kaliuzhin, VV; Kamaev, DIu; Solovtsov, MA; Tepliakov, AT, 2002) |
| "To assess antiischemic efficacy, safety and effect on myocardial perfusion of a course treatment with mildronate (as monotherapy and in combination with atenolol) in patients with postinfarction left ventricular dysfunction associated with moderate heart failure." | 5.10 | [The use of fatty acid beta-oxidation inhibitor mildronate as monotherapy or in combination with atenolol in patients with left ventricular dysfunction after myocardial infarction]. ( Mamchur, SE; Sankevitch, TV; Stepatcheva, TA; Teplyakov, AT, 2003) |
| "Plasma hormones were measured at baseline and months 3, 6, 12 and 24 in 91 patients with heart failure (left ventricular ejection fraction [LVEF] <25%) receiving 40 mg enalapril/day and double-blind atenolol (50 to 100 mg/day) or placebo." | 5.09 | Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. ( Berger, R; Bergler-Klein, J; Bojic, A; Frey, B; Hartter, E; Hülsmann, M; Moser, P; Pacher, R; Stanek, B; Strametz-Juranek, J; Sturm, B, 2001) |
| "The aim of this study was to compare the effects on left ventricular function and exercise tolerance of a selective beta-antagonist (atenolol) with those of another selective beta 1-antagonist with vasodilator properties (nebivolol) in patients with ischemic left ventricular dysfunction but no overt congestive heart failure." | 5.08 | Medium-term effects of beta-blockade on left ventricular mechanics: a double-blind, placebo-controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction. ( Chapelle, F; Hager, D; Pouleur, H; Rousseau, MF; Stoleru, L; Van Eyll, C; Van Nueten, L, 1996) |
| "We sought to determine the effect of nifedipine gastrointestinal therapeutic system (GITS) or atenolol on ischemic left ventricular dysfunction induced by mental stress." | 5.08 | Effects of therapy with nifedipine GITS or atenolol on mental stress-induced ischemic left ventricular dysfunction. ( Andrews, TC; Carlson, W; Cummings, N; Friedman, R; Jacobs, S; MacCallum, G; Mannting, F; Muller, JE; Parker, JD; Stone, PH; Tofler, GH, 1998) |
| " Following pretreatment with selective β2-AR antagonist ICI118,551 or selective β1-AR antagonist atenolol, cardiac anaphylaxis was induced by intracoronary injections of ovalbumin antigen." | 3.85 | Blockade of β2-adrenoceptor, rather than β1-adrenoceptor, deteriorates cardiac anaphylaxis in isolated blood-perfused rat hearts. ( Kuda, Y; Kurata, Y; Shibamoto, T; Tanida, M; Yang, W; Zhang, T, 2017) |
| "Baroreflex sensitivity was assessed in 287 patients with history of myocardial infarction and left ventricular ejection fraction < or =40% by phenylephrine test and was found to be depressed (4." | 3.72 | [Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction]. ( Bozhko, AA; Kanopskiĭ, SG; Staritskiĭ, AG, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 13 (81.25) | 29.6817 |
| 2010's | 1 (6.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kuda, Y | 1 |
| Shibamoto, T | 1 |
| Yang, W | 1 |
| Zhang, T | 1 |
| Tanida, M | 1 |
| Kurata, Y | 1 |
| Kaliuzhin, VV | 2 |
| Tepliakov, AT | 2 |
| Kamaev, DIu | 1 |
| Solovtsov, MA | 2 |
| Taniguchi, Y | 1 |
| Ueshima, K | 1 |
| Chiba, I | 1 |
| Segawa, I | 1 |
| Kobayashi, N | 1 |
| Saito, M | 1 |
| Hiramori, K | 1 |
| Teplyakov, AT | 1 |
| Sankevitch, TV | 1 |
| Stepatcheva, TA | 1 |
| Mamchur, SE | 1 |
| Kanopskiĭ, SG | 1 |
| Staritskiĭ, AG | 1 |
| Bozhko, AA | 1 |
| Wolff, CB | 1 |
| Checkley, SK | 1 |
| Bhageerutty, G | 1 |
| Bhatt, H | 1 |
| Johnston, A | 1 |
| Collier, DJ | 1 |
| Tachtsidis, I | 1 |
| Garvie, N | 1 |
| Rosenberg, ME | 1 |
| Benjamin, N | 1 |
| Malmqvist, K | 1 |
| Kahan, T | 1 |
| Edner, M | 1 |
| Bergfeldt, L | 1 |
| Panigada, S | 1 |
| Camporotondo, R | 1 |
| Repetto, A | 1 |
| Previtali, M | 1 |
| Rousseau, MF | 1 |
| Chapelle, F | 1 |
| Van Eyll, C | 1 |
| Stoleru, L | 1 |
| Hager, D | 1 |
| Van Nueten, L | 1 |
| Pouleur, H | 1 |
| Andrews, TC | 1 |
| Parker, JD | 1 |
| Jacobs, S | 1 |
| Friedman, R | 1 |
| Cummings, N | 1 |
| MacCallum, G | 1 |
| Mannting, F | 1 |
| Tofler, GH | 1 |
| Carlson, W | 1 |
| Muller, JE | 1 |
| Stone, PH | 1 |
| Stanek, B | 2 |
| Frey, B | 2 |
| Hülsmann, M | 2 |
| Berger, R | 2 |
| Sturm, B | 2 |
| Strametz-Juranek, J | 1 |
| Bergler-Klein, J | 1 |
| Moser, P | 1 |
| Bojic, A | 2 |
| Hartter, E | 1 |
| Pacher, R | 2 |
| Zaglavara, T | 1 |
| Haaverstad, R | 1 |
| Cumberledge, B | 1 |
| Irvine, T | 1 |
| Karvounis, H | 1 |
| Parharidis, G | 1 |
| Louridas, G | 1 |
| Kenny, A | 1 |
| Palmieri, V | 1 |
| Devereux, RB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-blind Evaluation of the Effects of Irbesartan and Atenolol on Cardiovascular Structure and Function in Subjects With Hypertension and Left Ventricular Hypertrophy[NCT00389168] | Phase 2/Phase 3 | 115 participants (Actual) | Interventional | 1995-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Difference in Diastolic Blood Pressure. Repeated measures multivariable analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| Atenolol | -16.3 |
| Irbesartan | -18.8 |
Changes in common carotid artery intima-media thickness, assessed by ultrasonography. (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | mm (Mean) |
|---|---|
| Atenolol | 0.03 |
| Irbesartan | -0.01 |
Safety was assessed by non-directed questions, and all observed and volunteered adverse events were recorded at each study visit. Serious adverse events were defined by, and reported according to the regulations of good clinical practice (GCP). none were considered related to the study medication. (NCT00389168)
Timeframe: Treatment period was baseline to 48 weeks
| Intervention | Participants (Number) |
|---|---|
| Atenolol | 5 |
| Irbesartan | 5 |
Repeated measures multivariate analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks. Data are presented as left ventricular mass in gram (g) indexed for body mass index (in m^2). (NCT00389168)
Timeframe: Baseline and 48 weeks
| Intervention | g/m^2 (Mean) | ||
|---|---|---|---|
| 12 weeks | 24 weeks | 48 weeks | |
| Atenolol | -1 | -6 | -14 |
| Irbesartan | -9 | -14 | -26 |
Venous plasma concentrations of angiotensin II were measured in order to study the possible associations between the activity of the renin-angiotensin-aldosteone system and changes in left ventricular mass. Further analyses of other components of the renin-angiotensin-aldosterone system and of other hormonal system (e.g. the sympathetic nervous system) have also been performed and published. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Data were log-transformed to avoid skewness before statistical evaluation. However, tabular data are given as mean values with 95% confidence to improve readability. (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | pmol/L (Mean) | ||
|---|---|---|---|
| Weel 12 | Week 24 | Week 48 | |
| Atenolol | -1.0 | -0.8 | -0.2 |
| Irbesartan | 3.0 | 3.3 | 10.0 |
Changes in left ventricular diastolic function from baseline to week 48 will be evaluated as the difference in E/A ratio. Conventional pulsed wave Doppler echocardiography was used for recordings of mitral inflow in. The peak of early (E) and late (A) mitral flow velocities were measured, and the E/A-ratio was calculated. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Some echocardiographic recordings at some time point may be of insufficient quality or missing, and the number of observations may not always correspond to the total number of participants at all time points. (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | ratio (Mean) | ||
|---|---|---|---|
| Week 12 | Week 24 | Week 48 | |
| Atenolol | 0.18 | 0.16 | 0.13 |
| Irbesartan | 0.10 | 0.04 | 0.10 |
1 review available for atenolol and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Atenolol; Calcium Channe | 2002 |
8 trials available for atenolol and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
[Effect of atenolol and trimetazidine on dispersion of cardiac rhythm in patients with moderately expressed postinfarction left ventricular dysfunction].
Topics: Anti-Arrhythmia Agents; Atenolol; Humans; Myocardial Infarction; Trimetazidine; Vasodilator Agents; | 2002 |
[Effect of long-term myocardial unloading with beta1-adrenoblocker atenolol on the state of the left ventricle in patients with moderate ischemic dysfunction of the heart as shown by doppler echocardiography].
Topics: Adrenergic beta-Antagonists; Atenolol; Echocardiography, Doppler; Female; Humans; Male; Middle Aged; | 2002 |
[The use of fatty acid beta-oxidation inhibitor mildronate as monotherapy or in combination with atenolol in patients with left ventricular dysfunction after myocardial infarction].
Topics: Adrenergic beta-Antagonists; Atenolol; Cardiovascular Agents; Drug Therapy, Combination; Humans; Mal | 2003 |
Cardiac repolarization and its relation to ventricular geometry and rate in reverse remodelling during antihypertensive therapy with irbesartan or atenolol: results from the SILVHIA study.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Diastole; Double-Blind Method; E | 2007 |
Medium-term effects of beta-blockade on left ventricular mechanics: a double-blind, placebo-controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Benzopyrans; Double-Blind Method; Ethanolamines; | 1996 |
Effects of therapy with nifedipine GITS or atenolol on mental stress-induced ischemic left ventricular dysfunction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Cross-Over Studies; Diastole; Double-Blind Metho | 1998 |
Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction.
Topics: Adrenergic beta-Antagonists; Atenolol; Atrial Natriuretic Factor; Biomarkers; Double-Blind Method; E | 2001 |
Long-term effect of atenolol on ejection fraction, symptoms, and exercise variables in patients with advanced left ventricular dysfunction.
Topics: Adrenergic beta-Antagonists; Atenolol; Double-Blind Method; Enalapril; Exercise Test; Exercise Toler | 2001 |
7 other studies available for atenolol and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Blockade of β2-adrenoceptor, rather than β1-adrenoceptor, deteriorates cardiac anaphylaxis in isolated blood-perfused rat hearts.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Anaphylaxis; Animals | 2017 |
[Beta blockade plus NO release. Patients with heart failure can be loaded more].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Ate | 2002 |
A new method using pulmonary gas-exchange kinetics to evaluate efficacy of beta-blocking agents in patients with dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Pressure; Cardiomyopathy, Dilated; Carteol | 2003 |
[Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti | 2004 |
Circulation time in man from lung to periphery as an indirect index of cardiac output.
Topics: Atenolol; Blood Circulation Time; Cardiac Output; Chest Pain; Diagnostic Techniques, Cardiovascular; | 2005 |
Role of dynamic intraventricular obstruction and protective effect of beta-blocking therapy in left ventricular apical ballooning syndrome: a case report.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Echocardiography, Stress; Female; He | 2009 |
Dobutamine stress echocardiography for the detection of myocardial viability in patients with left ventricular dysfunction taking beta blockers: accuracy and optimal dose.
Topics: Adrenergic beta-Antagonists; Atenolol; Cardiotonic Agents; Chronic Disease; Coronary Artery Bypass; | 2002 |